Characteristics of the COVID-19 and non-COVID-19 cohorts
| COVID-19 | Non-COVID-19 | |
| Number of subjects | 100 | 78 |
| Gender (females:males) | 47 females, 53 males | 45 females, 33 males |
| Age, years (mean±SD) | 36.4±18.7 years | 45.5±13.3 years |
| Disease severity category | 47 mild, 45 moderate, 5 severe, 3 critical | NA |
| Symptoms at admission, n (%) | ||
| Fever | 38 (38.0%) | NA |
| Diarrhoea | 17 (17.0%) | NA |
| Cough | 40 (40.0%) | NA |
| Sputum | 18 (18.0%) | NA |
| Sore throat | 8 (8.0%) | NA |
| Rhinorrhea | 19 (19.0%) | NA |
| Shortness of breath | 9 (9.0%) | NA |
| Comorbidities, n (%) | ||
| Hypertension | 11 (11.0%) | 11 (11.0%) |
| Hyperlipidaemia | 4 (4.0%) | 0 |
| Diabetes | 2 (2.0%) | 0 |
| Heart disease | 2 (2.0%) | 0 |
| Allergic disorders | 7 (7.0%) | 15 (15.0%) |
| HIV | 3 (3.0%) | 0 |
| Asthma | 2 (2.0%) | 2 (2.0%) |
| Received antibiotics during hospitalisation by disease severity, n (%) | ||
| Mild disease | 6 of 47 (12.8%) | NA |
| Moderate disease | 21 of 45 (46.7%) | NA |
| Severe disease | 4 of 5 (80.0%) | NA |
| Critical disease | 3 of 3 (100%) | NA |
| Received antivirals during hospitalisation, n (%) | ||
| Lopinavir/ritonavir | 38 of 100 (38.0%) | NA |
| Ribavirin | 30 of 100 (30.0%) | NA |
| Oseltamivir | 5 of 100 (5.0%) | NA |